Skip To Main Content
Alba Meya on Muck Rack

Alba Meya

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to Alba Meya’s profile

Articles by Alba Meya

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

|
By Jose Perez-Garcia, Javier Cortés, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escrivá-de-Romaní, Vega Iranzo, Nuria Ribelles, Florence Dalenc, Aleix Prat, Peter Schmid, Geraldine Gebhart, Frederik Marmé, Serena Di Cosimo, Sofia Braga, Marco Colleoni, Gabriele Antonarelli, Giulia Notini, Maria Gion, Lucía Sanz Verified, Elena Martinez-Garcia, Derek Dustin, Ana Amaya-Garrido, Daniel Alcalá-López, Jose Rodríguez-Morató, Leonardo Mina, Antonio Llombart-Cussac, Cristina Reboredo, Cinta Albacar, Noelia Martínez-Jáñez, Juan José García-Mosquera, Alba Meya, Jose Antonio Guerrero-Martínez, Mario Mancino
| Nature Verified
Abstract PHERGain was a randomized, non-comparative phase 2 trial evaluating a positron 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET)-guided, pathological complete response (pCR)-adapted strategy to omit chemotherapy in HER2-positive early breast cancer. Female patients with HER2-positive stages I–IIIA operable breast cancer (tumor size ≥ 1.5 cm) were randomized to receive chemotherapy plus trastuzumab and pertuzumab (HP; group A) or HP ± endocrine therapy (group B).
Open in Who Shared Issue with article?
Show More